A clinical trial explores whether tailoring gout treatment to the underlying cause of elevated uric acid can improve outcomes. Credit: Stock Should doctors rethink the standard gout treatment? Gout ...
Protalix BioTherapeutics, Inc. is rated a Buy due to robust FY26 revenue guidance of $78–83 million. Learn more about PLX ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results